Meyer Brigitte, Huelsmann Martin, Wexberg Paul, Delle Karth Georg, Berger Rudolf, Moertl Deddo, Szekeres Thomas, Pacher Richard, Heinz Gottfried
Department of Cardiology, Clinical Institute for Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria.
Crit Care Med. 2007 Oct;35(10):2268-73. doi: 10.1097/01.CCM.0000284509.23439.5B.
Natriuretic peptides emerged during recent years as potent prognostic markers in patients with heart failure and acute myocardial infarction. In addition, natriuretic peptides show strong predictive value in patients with pulmonary embolism, sepsis, renal failure, and shock. The present study tests the prognostic information of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) in an unselected cohort of critically ill patients.
Prospective, observational study.
A tertiary intensive care unit in a university hospital.
A total of 289 consecutive patients admitted to the intensive care unit during a 16-month period with the following data: age 64 +/- 14 yrs, male n = 191, Simplified Acute Physiology Score II of 52 +/- 24, mechanical ventilation n = 180 (62%), vasopressors n = 179 (62%), renal failure n = 24 (8%).
None.
Plasma NT-pro-BNP samples (Roche Diagnostics) were obtained on intensive care unit admission. Data are given as median [range]. Intensive care unit survivors had significantly lower NT-pro-BNP values compared with intensive care unit nonsurvivors (3394 [24-35,000] vs. 6776 [303-35,000] pg/mL, survivors vs. nonsurvivors, respectively, p = .001). Hospital survivors were characterized by significantly lower NT-pro-BNP values (2656 [24-35,000] vs. 8390 [303-35,000] pg/mL, survivors vs. nonsurvivors, respectively, p = .001). NT-pro-BNP levels were not significantly different in patients with primary cardiac diagnosis compared with those with a noncardiac admission diagnosis (4794 [26-35,000], n = 202 vs. 3349 [24-35,000], n = 87, cardiac vs. noncardiac, respectively, p = .28). In a logistic regression model, Simplified Acute Physiology Score II and NT-pro-BNP were independently associated with hospital survival (chi = 35.6, p = .0001 and chi = 11.3, p = .0008, Simplified Acute Physiology Score II and NT-pro-BNP, respectively). Areas under the receiver operating characteristic curves of NT-pro-BNP and Simplified Acute Physiology Score II were not statistically significant different regarding the prediction of outcome.
NT-pro-BNP on admission is an independent prognostic marker of outcome in an unselected cohort of critically ill patients. A single measurement of NT-pro-BNP might facilitate triage of emergency and intensive care unit patients.
近年来,利钠肽成为心力衰竭和急性心肌梗死患者强有力的预后标志物。此外,利钠肽在肺栓塞、脓毒症、肾衰竭和休克患者中显示出强大的预测价值。本研究在一组未经筛选的危重症患者中测试N末端B型利钠肽原(NT-pro-BNP)的预后信息。
前瞻性观察性研究。
大学医院的三级重症监护病房。
在16个月期间,共有289例连续入住重症监护病房的患者,其数据如下:年龄64±14岁,男性n = 191例,简化急性生理学评分II为52±24,机械通气n = 180例(62%),使用血管升压药n = 179例(62%),肾衰竭n = 24例(8%)。
无。
在重症监护病房入院时采集血浆NT-pro-BNP样本(罗氏诊断公司)。数据以中位数[范围]表示。与重症监护病房非幸存者相比,重症监护病房幸存者的NT-pro-BNP值显著更低(分别为3394[24 - 35,000]与6776[303 - 35,000]pg/mL,幸存者与非幸存者,p = 0.001)。医院幸存者的特征是NT-pro-BNP值显著更低(分别为2656[24 - 35,000]与8390[303 - 35,000]pg/mL,幸存者与非幸存者,p = 0.001)。原发性心脏诊断患者与非心脏入院诊断患者的NT-pro-BNP水平无显著差异(分别为4794[26 - 35,000],n = 202例与3349[24 - 35,000],n = 87例,心脏疾病与非心脏疾病,p = 0.28)。在逻辑回归模型中,简化急性生理学评分II和NT-pro-BNP与医院生存独立相关(χ = 35.6,p = 0.0001和χ = 11.3,p = 0.0008,分别为简化急性生理学评分II和NT-pro-BNP)。NT-pro-BNP和简化急性生理学评分II的受试者工作特征曲线下面积在预测结局方面无统计学显著差异。
入院时的NT-pro-BNP是一组未经筛选的危重症患者结局的独立预后标志物。单次测量NT-pro-BNP可能有助于急诊和重症监护病房患者的分诊。